Search Within

Michael Morris

Formats
  1. Meeting Abstract (275)
  2. Journal Article (267)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (583)
  2. Genitourinary Oncology Service (583)
  3. Solid Tumor Oncology Division (583)
  4. Radiology, Department of (164)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (141)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (24)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (44)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (44)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (583)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging
    Meeting Abstract

    Durack, J. C.; Alva, A. S.; Preston, M. A.; Pouliot, F.; Saperstein, L.; Carroll, P. R.; Pienta, K. J.; Rowe, S. P.; Patnaik, A.; Probst, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Seek and find: Current prospective evidence for prostate-specific membrane antigen imaging to detect recurrent prostate cancer
    Review

    Keegan, N. M.; Bodei, L.; Morris, M. J.
    European Urology Focus (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • The role of theranostics in prostate cancer
    Review

    O'Dwyer, E.; Bodei, L.; Morris, M. J.
    Seminars in Radiation Oncology (2021)

    Fulltext@MSK | Save
  • PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
    Meeting Abstract

    Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Shergill, A.; Zemla, T. J.; Emamekhoo, H.; Vaishampayan, U. N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol-A191402CD: A cluster-randomized trial
    Meeting Abstract

    Tilburt, J. C.; Pacyna, J. E.; Petereit, D. G.; Kaur, J. S.; Rapkin, B. D.; Grubb, R.; Chang, G. J.; Morris, M. J.; Kovac, E.; Sloan, J. A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA
    Meeting Abstract

    Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save